Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis

Francesca Chamian,Shao-Lee Lin,Edmund Lee,Toyoko Kikuchi,Patricia Gilleaudeau,Mary Sullivan-Whalen,Irma Cardinale,Artemis Khatcherian,Inna Novitskaya,Knut M. Wittkowski,James G. Krueger,Michelle A. Lowes

Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis

2007

Francesca Chamian
Shao-Lee Lin
Edmund Lee
Toyoko Kikuchi
Patricia Gilleaudeau
Mary Sullivan-Whalen
Irma Cardinale
Artemis Khatcherian
Inna Novitskaya
Knut M. Wittkowski
James G. Krueger
Michelle A. Lowes

Background Alefacept (anti-CD2) biological therapy selectively targets effector memory T cells (Tem) in psoriasis vulgaris, a model Type 1 autoimmune disease.

Keywords:

Psoriasis
Phorbol Myristate Acetate
Dermatologic agents
ANTIGENS CD
Autoimmune disease
Immunology
Effector
Immunologic memory
Medicine
Alefacept
psoriasis patient
mean fluorescence intensity

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations